C4 Therapeutics Inc
NASDAQ:CCCC
During the last 3 months C4 Therapeutics Inc insiders have not bought any shares, and sold 22.2k USD worth of shares. The stock price has increased by 13% over this period ( loading = false, 5000)" href="https://new.alphaspread.com/comparison/nasdaq/cccc/vs/indx/gspc">open performance analysis).
The last transaction was made on
Jan 16, 2026
by
Reyno Leonard
, who
sold
22.2k USD
worth of
CCCC shares.
During the last 3 months C4 Therapeutics Inc insiders have not bought any shares, and sold 22.2k USD worth of shares. The stock price has increased by 13% over this period ( loading = false, 5000)" href="https://new.alphaspread.com/comparison/nasdaq/cccc/vs/indx/gspc">open performance analysis).
The last transaction was made on
Jan 16, 2026
by
Reyno Leonard
, who
sold
22.2k USD
worth of
CCCC shares.
C4 Therapeutics Inc
Glance View
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.